What Was Approved?
On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae) as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Awiqli is a long-acting insulin designed to be administered once weekly.
How Is Awiqli Used?
Awiqli is injected under the skin in the:
- Abdomen
- Thigh
- Upper arm
The dose must be individualized according to factors such as current insulin treatment, glucose readings, metabolic needs, and treatment goals. Patients switching from a daily basal insulin require specific dosing instructions and closer glucose monitoring during the transition.
What Is Important About the Concentration?
Awiqli is a highly concentrated insulin containing 700 units/mL (U-700) and is supplied in prefilled FlexTouch pens.
The FDA label specifically warns not to transfer Awiqli from the pen into a syringe, because doing so could result in overdose and severe hypoglycemia.
Patients should check the insulin label before every injection to reduce the risk of medication errors.
What Are the Main Safety Concerns?
The most important risk with insulin therapy is hypoglycemia, or dangerously low blood sugar.
The FDA label also includes warnings for:
- Severe allergic reactions
- Low potassium levels
- Medication errors and accidental overdose
- Changes in blood sugar when the insulin regimen is changed
- Fluid retention and possible heart failure when used with certain thiazolidinedione diabetes medicines
What Are Common Side Effects?
Adverse reactions associated with Awiqli include:
- Hypoglycemia
- Injection-site reactions
- Weight gain
- Swelling
- Rash or itching
- Lipodystrophy at injection sites
Rotating injection sites can help reduce certain local skin changes.
Is Awiqli Approved for Type 1 Diabetes?
The current FDA-approved indication is specifically for adults with type 2 diabetes mellitus.
It should not be assumed to be approved for other types of diabetes unless the FDA labeling is updated.
Bottom Line
Awiqli (insulin icodec-abae) is a newly FDA-approved once-weekly long-acting insulin for adults with type 2 diabetes.
Its weekly dosing offers a different basal-insulin schedule, but careful dosing, glucose monitoring, and prevention of medication errors are particularly important because it is a concentrated U-700 insulin.
Sources
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.
- U.S. Food and Drug Administration (FDA) — Awiqli (insulin icodec-abae) Prescribing Information, March 2026.
- U.S. Food and Drug Administration (FDA) — Awiqli Approval Package, March 26, 2026.